August 6, 2014

African American Prostate Cancer Disparity Summit
Thursday, September 25th
Friday, September, 26 2014



Our Partners










PHEN Webcast, August 13th at 6:00 pm ET

An Immunotherapy Vaccine to Prevent the Recurrence of Localized Prostate Cancer
The PHEN August webcast will present a potential breakthrough in preventing the recurrence of prostate cancer when treated at the localized level with the immunotherapy ProstAtak.

Estuardo Aguilar-Cordova, M.D. inf., Ph.D.

Chairman and CEO, Advantagene, Inc. 

Webcast viewers will be able to submit questions via: 

Facebook: ProstateHealthEducationNetwork
Twitter: @RapCancer

Please join the webcast on Wednesday, August 13, 2014, at 6:00 pm ET! Visit

About ProstAtak™

ProstAtak uses an innovative technique known as Gene Mediated Cytotoxic Immunotherapy (GMCI™) to kill tumor cells and stimulate a cancer vaccine effect. The idea is to "jump-start" the body's immune system so it can better detect and destroy residual cancer cells that pose a risk of the cancer returning.  ProstAtak is designed to work together with standard radiation therapy and has resulted in lower than expected recurrence rates in earlier clinical trials. In a phase 2 study, the rate of recurrence was reduced from an expected 30% to 10%.  At present, ProstAtak is the only vaccine product in development for preventing recurrence in localized prostate cancers. 
ProstAtak is currently in a Phase 3 clinical trial under an FDA approved special protocol assessment (Fast-track), and is sponsored by Advantagene, Inc., a Boston, Massachusetts area biopharmaceutical company.
Join the webcast to learn more about ProstAtak and the phase 3 clinical trial.


500 Victory Rd. | Fourth Floor | Quincy, MA 02171
Tel. 617.481.4020 | Fax 617.481.4021 | [email protected]

Like us on Facebook   Follow us on Twitter    View our videos on YouTube     Visit our blog